•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Insiders Are Scooping Up These 5 Stocks Now
Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
What Makes Lineage Cell (LCTX) a New Buy Stock
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
Lineage to Present at 2024 BIO International Convention
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Call Transcript
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Lineage Announces Changes to Board of Directors
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.